Rufinamide is an antiepileptic agent primarily used for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a severe form of epilepsy. It prolongs the inactive state of voltage-gated sodium channels, stabilizing neuronal activity and reducing seizure frequency, including drop attacks and tonic-atonic seizures. This high-purity (≥98%) white to off-white powder (melting point 235-245°C) is suitable for pharmaceutical research, development, and API manufacturing.